European specialist investor in healthcare, GHO Capital, has acquired a majority stake in Sterling Pharma Solutions, a specialist in complex and difficult to manufacture APIs.
Headquartered in Newcastle-upon-Tyne, Sterling is a leading provider of API development and manufacturing. The company is a provider of specialist services from clinical development through market launch to commercial supply.
Outsourced small molecule API development and manufacturing is growing steadily at around 7% per year. This is overlaid with a long-term trend towards increasing molecule complexity, driving higher market growth rates in complex chemistry.
GHO Capital brings extensive sectoral expertise and networks in the global pharmaceutical and animal health industries to support Sterling’s international growth.
Kevin Cook, CEO of Sterling Pharma Solutions, said: “We are delighted to partner with GHO Capital, whose expertise in the pharmaceuticals space and track record of supporting companies to expand internationally will be invaluable in facilitating the next stage of our growth in Europe and in the US.”
Alan MacKay, Partner at GHO Capital, said: “Sterling provides a compelling opportunity to partner with a best-in-class management team to support the global demand for complex chemistry in pharmaceuticals.”